What one share of Revelation Biosciences holds
Revelation is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. We have multiple ongoing programs to evaluate Gemini, including GEM-AKI as a treatment for acute kidney injury (“AKI”) and GEM-CKD as a treatment for chronic kidney disease (“CKD”).
Revelation Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$8.37 |
|---|---|
| Cash and investments | $2.94 |
| Book value | $2.58 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | — | −$1,052 | $1.34 | −$1,283 | — | — |
| 2025 | — | −$23.95 | — | — | — | $5.59 |
Common questions about Revelation Biosciences
How much does one share of Revelation Biosciences earn?
Over the last 12 months, Revelation Biosciences lost $8.37 for each share.
Does Revelation Biosciences pay a dividend?
Revelation Biosciences didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Revelation Biosciences’s book value per share?
Revelation Biosciences’s book value is $2.58 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Revelation Biosciences have?
Each share of Revelation Biosciences has $2.94 of cash and investments, as of June 30, 2026.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.